All In Biotech

Drug Trial Radar · NCT07727486

A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Oral ICP-488 in Participants With Primary Sjögren's Syndrome (pSjS)

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Dec 2028

Study completion Mar 2029

Sponsor

Sponsor type
Industry
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjögren's syndrome (pSjS).

Conditions

  • Primary Sjögren's Syndrome

Interventions

  • ICP-488 TabletsDrug

    Specified dose on specified days

  • ICP-488 PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in EULAR sjögren's syndrome disease activity index(ESSDAI ) at Week 24Time frame: Baseline, Week 24

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Peking

    Beijing, Beijing Municipality, China

  • Chongqing Traditional Chinese Medicine Hospital

    Chongqing, Chongqing Municipality, China

  • "Southwest Hospital, Army Medical University (The First Hospital Affiliated to Army Medical University)"

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China

  • "Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School"

    Nanjin, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Bethune First Hospital of Jilin University

    Changchun, Jilin, China

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Tianjin First Central Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Jinhua Municipal Central Hospital

    Jinhua, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.